Kind-Philipp-Foundation for Research in Pediatric Oncology
XXXV. Annual Meeting | June 5-8, 2024

General information for participants

Arrival and registration

Arrival and registration

Registration and room allocation will take place at 16:00 in Undeloh (in front of the “Undeloher Hof”), where you also have the opportunity to park your car. After registration you should make your way to Wilsede, where you will be welcomed at the conference location. You will have time to meet the other participants and collect your name tags.

Information for presenters

Information for presenters

Presentations are 10 + 2 min from Wednesday through to Friday. Short talks given on Saturday are 7 + 2 min long. The exceptions will be our key note speakers for the invited lectures, who will be given 30 min time. Due to the large number of participants this year, we kindly ask you to stay within the time limit. We recommend to use a 16:9 formate for your presentation slides. Please also refer to the information you received via E-mail regarding the upload of your presentation. We have microsoft and IOS devices available for you to use to check and display your presentation from. Our friendly technical support will be located in the back of the conference room and available to assist you.

During your stay

During your stay

We advise you check the weather forecast, before you travel to Wilsede. The weather in July is usually fairly sunny and warm, so we recommend sun screen. However it might cool down in the evening and past events have also been accompanied by rain. We also note, that the roads/paths between Underloh and Wilsede are not paved and you may consider this when choosing footwear.

WEDNESDAY, June 5, 2024

16:00 – 17:30

16:00 – 17:30

Arrival and registration

Registration

17:30 – 17:45

17:30-17:45

Opening speech

Welcome speech

by Rolf Marschalek

17:45 – 19:00

17:45 – 19:00

(A) Appetizers

(A) Appetizers

Chair: Rolf Marschalek

A.1 The testicular niche – heterogeneity in leukemic cell adaptation to the new immunemicroenvironment
Maïa Pesic; Berlin

A.2 Interplay between macrophages and AML blast in pediatric acute myeloid leukemia
Alicia Perzolli; Utrecht

A.3 Enhancing Therapy for TP53-Deficient Rhabdomyosarcomas
Ebrahem Hamed; Freiburg

A.4 Dual targeting of FLT3-ITD and CLK by screened donated chemical probes in acute myeloid leukemia
Stephanie Laszig; Frankfurt am Main

A.5 Results of the RIST-rNB-2011 trial for relapsed or refractory neuroblastoma
Selim Corbacioglu; Regensburg

A.6 Deciphering the Epigenetic Landscape of Relapsed Myeloid Leukemia in Children with Down Syndrome
Katja Rohde; Frankfurt am Main

19:00 – 19:30

19:00 – 19:30

Invited Lecture I

(B) Invited lecture I

Chair: Martin Stanulla

Prof. Dr. med. Florian Heidel

B.1 Effectors of oncogenic signaling

Director of the Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany

19:30

19:30

Dinner

Dinner

THURSDAY, June 6, 2024

09:00 – 10:30

09:00 – 10:30

(C) Translation and therapy I

(C) Translation and therapy

Chair: Basant Thakur

C.1 Evaluation of Navitoclax (ABT-263) as a promising Therapy for Pediatric Acute Myeloid Leukemia
David Agha-Mir-Salim; Frankfurt am Main

C.2 The activation of TP53 pathway is a therapeutic vulnerability in NUP98::KDM5A+ Pediatric Non-Down Syndrome AMKL
Luca N. Cifarelli; Frankfurt am Main

C.3 Inhibition of Cyclin-dependent Kinase 9 Leads to Rapid and Effective Apoptosis Induction in Acute Lymphoblastic Leukemia
Colin Fortner; Ulm

C.4 A structurally improved Decitabine analogue induces increased anti-leukemia activity in vivo
Annika Fröhlich; München

C.5 siRNA Delivery for the Treatment of RUNX1::ETO Driven Acute Myeloid Leukemia
L.Daniel Mata Casimiro; Utrecht

C.6 Preemptive Targeting of Preleukemic Cells in Down Syndrome with Pathway-Directed Therapies
Anna-Lena Schmell; Frankfurt am Main

C.7 Pharmacotyping identifies venetoclax as effective salvage therapy in primary refractory MLLT10::PICALM acute leukemia
Alexandra Niedermayer; Ulm

10:30 – 11:00

10:30 – 11:00

Coffee break

Coffee break

11:00 – 12:30

11:00 – 12:30

(D) Signal transduction

(D) Signal transduction

Chair: Pablo Menendez

D.1 Reverse engineering BCP-ALL signaling with large knock-out screens
Mathurin Dorel; Berlin

D.2 STAT3β represses interferon signaling in acute myeloid leukemia contributing to favorable disease outcomes
Sophie Edtmayer; Krems

D.3 STAT3 isoforms – Striking the balance
Stefanie Weiss; Krems

D.4 Effects of the allosteric tyrosine kinase inhibitor asciminib on bone metabolism
Tobias Fuhrmann; Erlangen

D.5 Deciphering kinase dependent and independent functions of CDK8 in lymphoid and myeloid leukemia
Elisabeth Gamper; Vienna

D.6 Functional characterization of T389 phosphorylation of RNA-binding protein La in neuroblastoma cells
Gunhild Sommer; Regensburg

D.7 Cdk6’s functions are critically regulated by its unique C-terminus
Alessia Schirripa; Vienna

12:30 – 14:00

12:30 – 14:00

Lunch (Wilsede, Heidemuseum)

Lunch (Wilsede, Heidemuseum)

14:00 – 14:30

14:00 – 14:30

Invited Lecture II

(E)Invited Lecture II

Chair: Olaf Heidenreich

Professor Brain Huntly

E.1 Aberrant gene regulatory complexes in leukemia

Professor of Leukaemia Stem Cell Biology,
Head of Department of Haematology, University of Cambridge, UK

14:30 – 16:00

(F) Immunotherapy I

(F) Immunotherapy I

Chair: Owen Williams

F.1 CD127-targeted immunotherapy outperforms Imatinib in preclinical models of ABL-class fusion positive BCP-ALL
Anna Dietterle; Kiel

F.2 Adaptive NK cells in combination with tyrosine-kinase inhibition for the treatment of Ph- like ALL
Zoya Eskandarian; Hamburg

F.3 Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy
Anna-Katharina Franke; Hamburg

F.4 A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 is Active in Preclinical Models of T-ALL
Matthias Peipp; Kiel

F.5 Comparison of CD123- and CD33-CAR-NK cell preparations in a xenograft mouse model for treatment of AML
Fenja Gierschek; Frankfurt am Main

F.6 Novel treatment approaches for pediatric high-grade gliomas with MYCN amplification
Johanna C. von Pölnitz; Hamburg

F.7 A new recombinant oncolytic measles virus for therapy of ALL and assessment of its toxicity
Sabine Heinze; Ulm

14:30 – 16:00

16:00 – 16:30

16:00 – 16:30

Coffee break

Coffee break

16:30 – 18:00

16:30 – 18:00

(G) Molecular mechanisms of disease I

(G) Molecular mechanisms of disease I

Chair: Irmela Jeremias

G.1 The role of lncRNAs in fusion-oncoprotein containing oncogenic biomolecular condensates in Acute Myeloid Leukemia
Melanie Allram; Vienna

G.2 Modulating ubiquitin signaling to control cell death and necroinflammation in patient-derived human mammary organoids
Kaja N. Wächtershäuser; Frankfurt am Main

G.3 Deciphering the NPM1c epigenetic network in acute myeloid leukemogenesis
Sara Barros da Gama; Frankfurt am Main

G.4 Replication stress associated micronucleation of extrachromosomal DNA
Lotte Brückner; Berlin

G.5 Deciphering the role of KANSL1 mutations in the development of Myeloid Leukemia in children with Down Syndrome (ML-DS)
Sònia Cases i Palau; Frankfurt am Main

G.6 Exploiting MYB-dependent vulnerabilities for novel therapeutics in acute myeloid leukaemia
Noelia Che; London

G.7 Investigating the role of OTULIN and the regulation of linear ubiquitination in the pathogenesis of ABC-DLBCL
Gulustan Celik; Frankfurt am Main

18:30 – 19:00

Invited Lecture III

(H) Invited lecture III

Chair: Jan-Henning Klusmann

Prof.Dr.med. Anton Henssen

H.1 Extrachromosomal Oncogene Amplification in Cancer

Head of preclinical research, Attending Physician,
Pediatrician, Charité – Universitätsmedizin Berlin, Germany

18:30 – 19:00

19:00

19:00

Dinner

Barbecue

FRIDAY, June 7, 2024

09:00 – 10:30

09:00 – 10:30

(I) Immunotherapy

(I) Immunotherapy II

Chair: Katrin Ottersbach

I.1 Decitabine enhances antibody-dependent effects of Daratumumab immunotherapy in acute lymphoblastic leukemia models
Julia Heymann; Kiel

I.2 Exploring Synergistic Approaches to Enhance Blinatumomab’s Efficacy in Acute Lymphoblastic Leukemia
Juan Lazaro; Berlin

I.3 CD19-CAR-NK cells show ability to initiate diverse mechanisms of cancer cell death in hematological malignancies
Alina Moter; Frankfurt am Main

I.4 HDAC7 induction prevents immune escape in high-risk infant pro-B-ALL
Íngrid Ocón-Gabarró; Badalona

I.5 Primary CAR-NK cells targeting B7-H3 as a novel experimental immunotherapeutic strategy against glioblastoma
Sophia Thul; Frankfurt am Main

I.6 IL-7R immunotherapy combined with chemotherapy effectively reduces xenograft acute lymphoblastic leukemia (ALL)
Lennart Lenk; Kiel

I.7 EGFR/EGFRvIII-targeted CAR-NK cells as a promising allogeneic cell therapy for the treatment of solid tumors
Lisa M. Reindl; Frankfurt am Main

10:30 – 11:00

10:30 – 11:00

Coffee break

Coffee break

11:00 – 12:30

11:00 – 12:30

(J) Malignant cell biology

(J) Malignant cell biology

Chair: Florian Grebien

J.1 CRISPR/Cas9-mediated KMT2A-rearrangements for the development of leukaemia mouse models
Tamara Benz; Frankfurt am Main

J.2 Inhibition of small EVs secretion and its implication on cytoplasmic DNA sensing and cancer immunogenicity in AML
Jamal Ghanam; Essen

J.3 Replication stress induces extrachromosomal DNA clustering and lagging during anaphase
Alexander Herrmann; Berlin

J.4 Targeting ATRX-Deficient Hepatoblastoma
Negin Razizadeh; Munich

J.5 Targeting the non-coding and stem cell signature in childhood acute myeloid leukemia
Leah Schüler; Frankfurt am Main

J.6 Dissecting enhancers at nucleotide resolution in pediatric cancer
Sandra Wittibschlager; Vienna

J.7 Molecular differences of paired primary and recurrent atypical teratoid/rhabdoid tumors (AT/RT)
Lea Altendorf; Hamburg

12:30 – 14:00

12:30 – 14:00

Lunch (Wilsede, Heidemuseum)

Lunch (Wilsede, Heidemuseum)

14:00 – 15:30

14:00 – 15:30

(K) Biomarkers and diagnostics

(K) Biomarkers
and diagnostics

Chair: Meinolf Suttorp

K.1 Naturally occurring antibodies as next-generation immunotherapeutics for high-risk neuroblastoma
Isabelle A. Bley; Hamburg

K.2 Polyphosphates are regulators of metabolic homeostasis upon amino acid starvation in drug resistant leukemia cells
Büsra Cinar; Hannover

K.3 From a rare childhood leukemia to novel biomarkers and therapeutic targets in AML – lessons from a cross-entity study
Mark Hartmann; Heidelberg

K.4 Validation of ICH Q2(R2) compliant flow cytometry-based Quality Control for the characterization of CAR-NK cell products
Juliane Schlüter; Frankfurt am Main

K.5 Distribution of BCR::ABL1 transcript types and response to therapy in pediatric patients with chronic myeloid leukemia
Esra Seiser; Erlangen

K.6 Unraveling the role of PDHA1 in neuroblastoma metastasis
Giovanna Stadler; Ulm

K.7 Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B-cell neoplasias
Mercedes Guerrero-Murillo; Barcelona

15:30 – 16:00

Coffee break

15:30 – 16:00

Coffee break

16:00 – 17:00

(L) Tumor microenviroment

(L) Tumor microenvironment

Chair: Dirk Heckl

L.1 Exploring the immune microenvironment dynamics in AML progression via single cell analysis
Federica Valigi; Basel

L.2 Exosome-liposome hybrid system for reprogramming medulloblastoma and glioblastoma immunosuppressive microenvironment
Ommolbanin AsadPour; Essen

L.3 YBX1 protein in AML-derived small extracellular vesicles reduces mesenchymal stem cell differentiation to osteoblasts
Venkatesh K. Chetty; Essen

L.4 MiR-181a in Pediatric Acute Lymphoblastic Leukemia of the Central Nervous System
Vera Münch; Ulm

L.5 Single Cell Sequencing to Characterize the Bone Marrow Microenvironment in KMT2A Rearranged Pediatric AML
Elizabeth K. Schweighart; Utrecht

17:00 – 18:00

(M) Molecular mechanisms of disease II

(M) Molecular mechanisms of disease II

Chair: Marie-Laure Yaspo

M.1 Dysfunction of specific components of the spindle assembly checkpoint drives vincristine response in leukemia cells
Tim Dolgner; Hannover

M.2 Targeted modulation of HDAC7 improves the outcome of hematological malignancies
Mar Gusi-Vives; Badalona

M.3 IGF2BP3 as an interesting target gene in t(4;11) leukemia
Thomas Hanewald; Frankfurt am Main

M.4 Functional role of histone variant macroH2A1 (H2afy) in acute myeloid leukemia
Chen-Jen Hsu; Hannover

M.5 Regulatory mechanisms of the DLK1-DIO3 locus in the hematopoietic system and pediatric acute myeloid leukemia
Lonneke Verboon; Frankfurt am Main

17:00 – 18:00

18:00 – 18:30

Coffee break

18:00 – 18:30

Coffee break

18:30 – 19:00

Invited Lecture IV

(N) Invited lecture IV

Chair: Rolf Marschalek

Prof.Dr.med. Katrin Ottersbach

N.1 The developmental origin and biology of infant leukemia

Professor of Developmental Haematology / Cancer Research UK Fellow, The University of Edinburgh, UK

19:00 – 19:15

Wilsede Award

18:30 – 19:00

19:00 – 19:15

Wilsede award

19:15

Dinner

19:15

Dinner

SATURDAY, June 8, 2024

09:00 – 10:15

09:00 – 10:15

(O) Short talks I

(O) Short talks I

Chair: Jasper de Boer

O.1 The nanoparticle-mediated delivery of therapeutic siRNA’s targeting fusion genes in leukemia
Manisha Du Plessis; Utrecht

O.2 Targeting the fetal transcriptional landscape of pediatric AML
David Groll; Frankfurt am Main

O.3 Discovery of Oncogenic Mechanisms regulated by EZH2-regulated RBPs in AML
Xiang Fan; Frankfurt am Main

O.4 Characterization of the stromal microenvironment in B-cell Acute Lymphoblastic Leukemia
Bexultan Kazybay; Utrecht

O.5 Engineering multifunctional GRP78-CAR CIK cells to target relapsed/refractory pediatric AML
Elisa Hopke; Frankfurt am Main

O.6 Single cell RNA sequencing unravels targetable interaction axes in B-cell acute lymphoblastic leukemia
Feiko Nuijten; Utrecht

O.7 Exploring the translational potential of EZH2-controlled fetal gene signature in AML
Elif Özcan; Frankfurt am Main

O.8 ABC transporters modulate the response of AML cells to Menin-MLL inhibitors
Martin Piontek; Vienna

10:15 – 10:45

10:15 – 10:45

Coffee break

Coffee break

10:45 – 12:00

10:45 – 12:00

(P) Short talks II

(P) Short talks II

Chair: Mark Hartmann

P.1 A Novel Bone Marrow Organoid Platform for Studying Hematological Malignancies
Sebastian Ramisch; Utrecht

P.2 Exploring BCL-xL inhibition for the treatment of pediatric acute megakaryoblastic leukemia
Liz-Mette Reitemeier; Frankfurt am Main

P.3 Probing the non-coding cancer transcriptome for context-dependent vulnerabilities
Moritz J. Schanzer; Munich

P.4 The impact of extrachromosomal MDM2 amplifications on tumor heterogeneity and treatment resistance
Rachel Schmargon; Berlin

P.5 Unveiling the Molecular Complexity of AML through Advanced Multi-Omics Analysis and Machine Learning
Konstantin Schuschel; Frankfurt am Main

P.6 High-throughput drug screening of triple combinations in pediatric acute myeloid leukemia
Johannes Haas; Frankfurt am Main

P.7 Investigating the Role of CTCF in Antisense Transcription: Insights and Implications in AML
Zijin Zhang; Frankfurt am Main

P.8 γ/δ-T cells for the immunotherapy of pediatric acute lymphoblastic leukemia with blinatumomab
Juri Dubke; Hamburg

P.9 Combination of BH3 mimetics with NK cell-based immunotherapy as a potential novel treatment option for pediatric sarcoma
Raquel S. Pereira; Frankfurt am Main

12:00 – 13:00

12:00 – 13:00

Lunch (Wilsede, Heidemuseum)

Lunch (Wilsede, Heidemuseum)

13:00

13:00

Departure

Departure

Many thanks for making this meeting possible:

Many thanks for making this meeting possible: